|
WO2020153279A1
|
|
Process for the differential solubility-driven asymmetric transformation of substituted 2h-chromene-3-carboxylic acids
|
|
US2018193324A1
|
|
Use of EP4 receptor antagonists in the treatment of cartilage disease
|
|
US2019365680A1
|
|
Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
|
|
US2018125832A1
|
|
Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
|
|
KR20150135329A
|
|
Therapeutic Agent For Eye Disorder
|
|
MX2015013328A
|
|
Use of ep4 receptor antagonists in the treatment of cartilage disease.
|
|
TW201431847A
|
|
Salt and crystal form
|
|
BR122012015772B1
|
|
IMIDAZOLE COMPOUNDS Fused TO ATILA OR HETEROARIL
|
